510(k) Report

510(k) · Cleared

Cleared

NeuMoDx GBS Assay

K173725510(k) TraditionalCleared Jun 26, 2018203-day reviewClass I21 CFR 866.3740

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Neumodx Molecular, Inc. · NJR Nucleic Acid Amplification Assay System, Group B Streptococcus, Direct Specimen Test

Cleared on Jun 26, 2018 as substantially equivalent to K090191 (Handylab, Inc., 2010) after a 203-day review. Its family tree reaches back 5 generations to 1994.

Decided
Jun 26, 2018
Review
203 days
Class
Class I
Product code
NJR
Recalls
None
Predicates
1

Its longest line of descent runs back 5 generations to K936112 (1994). No later device cites it as a predicate yet.

  1. Root · 5 generations backK936112 Strep B OiaBiostar, Inc. · 1994
  2. 4 generations backK991828 Strep B OiaBiostar, Inc. · 1999
  3. 3 generations backK022504 Idi-Strep B AssayInfectio Diagnostic, Inc. · 2002
  4. 2 generations backK062948 Smart GBS and Smartcycle DX System and Software, Version 1.7BCepheid · 2006
  5. 1 generation backK090191 Handylab GBS Assay, Handylab Jaguar Instrument, Handylab Dna…Handylab, Inc. · 2010
  6. This deviceK173725 NeuMoDx GBS AssayNeumodx Molecular, Inc. · 2018
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−5K936112Strep B OiaBiostar, Inc.1994—
−4K991828Strep B OiaBiostar, Inc.1999—
−3K022504Idi-Strep B AssayInfectio Diagnostic, Inc.2002—
−2K062948Smart GBS and Smartcycle DX System and Software, Version 1.7BCepheid2006—
−1K090191Handylab GBS Assay, Handylab Jaguar Instrument, Handylab Dna Extraction Strip…Handylab, Inc.2010—
0 (this device)K173725NeuMoDx GBS AssayNeumodx Molecular, Inc.2018—
FIG. 1 — Lineage of K173725, 1994–2018Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in NJR? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new NJR device

  1. #1 K222638 Xpert® Xpress GBS, GeneXpert® Dx System…score 7.0 · 4 generations · no Class I recall
  2. #2 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K090191Handylab GBS Assay, Handylab Jaguar Instrument, Handylab Dna Extraction Strip, Handylab…
Summary page 4
…Class I FDA Review Panel: 83 - Microbiology Regulation Number: 21 CFR §866.3740 3. PREDICATE DEVICE BD Max™ GBS Assay (K090191) 4. DEVICE DESCRIPTION The NeuMoDx™ GBS Assay (Subject Device) as implemented on the…
Handylab, Inc.2010—

Also cleared against K090191: 1 other device →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 24 years and passes through 5 companies; a new generation was cleared every 4.1 years on median.
  • None of the 5 ancestors has a recall.
  • 1 other device also cites its predicate K090191.

How does its category compare?

All NJR devices

NJR Nucleic Acid Amplification Assay System, Group B Streptococcus, Direct Specimen Test: FDA decisions, review times, recalls and adverse event reports over 20 years. 2018, this device’s year, is highlighted.

FDA decisions per year · NJR

1in 2023

2010: 12011: 12012: 32013: 12015: 12016: 12017: 22018: 32022: 12023: 1
2007high 3 (2012) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · NJR

87in 2018

2012: 162 days median2018: 87 days median
2007high 162 (2012) · low 87 (2018)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · NJR

1in 2025

2007: 12011: 12012: 22015: 12022: 12024: 22025: 1
2007high 2 (2012) · low 0 (2008)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · NJR

14in 2024

2014: 12017: 12020: 12021: 22022: 32023: 82024: 14
2007high 14 (2024) · low 0 (2007)2025

MAUDE reports naming product code NJR, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—10
20080—00
20090—00
20101—00
20111—10
2012316220
20131—00
20140—01
20151—10
20161—00
20172—01
201838700
20190—00
20200—01
20210—02
20221—13
20231—08
20240—214
20250—10
20260—0—

What is it indicated for?

The NeuMoDx™ GBS Assay as implemented on the NeuMoDx™ 288 Molecular System is a qualitative in vitro diagnostic test designed to detect Group B Streptococcus (GBS) DNA from 18-24 hour Lim broth enrichments of vaginal/rectal swabs from pregnant women. The test incorporates automated DNA extraction to isolate the target nucleic acid from the specimen and real-time polymerase chain reaction (PCR) to detect an 88 bp region of the pcsB gene sequence in the…

Read the full statement (117 words)

The NeuMoDx™ GBS Assay as implemented on the NeuMoDx™ 288 Molecular System is a qualitative in vitro diagnostic test designed to detect Group B Streptococcus (GBS) DNA from 18-24 hour Lim broth enrichments of vaginal/rectal swabs from pregnant women. The test incorporates automated DNA extraction to isolate the target nucleic acid from the specimen and real-time polymerase chain reaction (PCR) to detect an 88 bp region of the pcsB gene sequence in the Streptococcus agalactiae chromosome. Results from the NeuMoDx™ GBS Assay can be used as an aid in determining colonization status in antepartum women.

The NeuMoDx™ GBS Assay does not provide susceptibility results. Cultured isolates are needed for performing susceptibility testing as recommended for penicillin-allergic women.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K173725: NeuMoDx GBS Assay.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K173725

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026